These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 24170759)

  • 1. Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.
    Miller ME; Williamson JD; Gerstein HC; Byington RP; Cushman WC; Ginsberg HN; Ambrosius WT; Lovato L; Applegate WB;
    Diabetes Care; 2014; 37(3):634-43. PubMed ID: 24170759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.
    Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME
    BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial.
    Hempe JM; Liu S; Myers L; McCarter RJ; Buse JB; Fonseca V
    Diabetes Care; 2015 Jun; 38(6):1067-74. PubMed ID: 25887355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.
    Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S;
    BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.
    Launer LJ; Miller ME; Williamson JD; Lazar RM; Gerstein HC; Murray AM; Sullivan M; Horowitz KR; Ding J; Marcovina S; Lovato LC; Lovato J; Margolis KL; O'Connor P; Lipkin EW; Hirsch J; Coker L; Maldjian J; Sunshine JL; Truwit C; Davatzikos C; Bryan RN;
    Lancet Neurol; 2011 Nov; 10(11):969-77. PubMed ID: 21958949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Intensive Versus Standard Blood Glucose Control in Patients With Type 2 Diabetes Mellitus in Different Regions of the World: Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Sardar P; Udell JA; Chatterjee S; Bansilal S; Mukherjee D; Farkouh ME
    J Am Heart Assoc; 2015 May; 4(5):. PubMed ID: 25944874
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials.
    Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C
    BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.
    Reaven PD; Moritz TE; Schwenke DC; Anderson RJ; Criqui M; Detrano R; Emanuele N; Kayshap M; Marks J; Mudaliar S; Harsha Rao R; Shah JH; Goldman S; Reda DJ; McCarren M; Abraira C; Duckworth W;
    Diabetes; 2009 Nov; 58(11):2642-8. PubMed ID: 19651816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparative effects of intensive glucose lowering in diabetes patients aged below or above 65 years: Results from the ADVANCE trial.
    Ohkuma T; Chalmers J; Cooper M; Hamet P; Harrap S; Marre M; Mancia G; Poulter N; Woodward M
    Diabetes Obes Metab; 2021 Jun; 23(6):1292-1300. PubMed ID: 33539672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.
    Meier M; Hummel M
    Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
    ; Patel A; MacMahon S; Chalmers J; Neal B; Billot L; Woodward M; Marre M; Cooper M; Glasziou P; Grobbee D; Hamet P; Harrap S; Heller S; Liu L; Mancia G; Mogensen CE; Pan C; Poulter N; Rodgers A; Williams B; Bompoint S; de Galan BE; Joshi R; Travert F
    N Engl J Med; 2008 Jun; 358(24):2560-72. PubMed ID: 18539916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.
    Riddle MC; Ambrosius WT; Brillon DJ; Buse JB; Byington RP; Cohen RM; Goff DC; Malozowski S; Margolis KL; Probstfield JL; Schnall A; Seaquist ER;
    Diabetes Care; 2010 May; 33(5):983-90. PubMed ID: 20427682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C; Jun M; Badve SV; Pilmore H; White SL; Hawley C; Cass A; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2017 Feb; 2(2):CD009966. PubMed ID: 28238223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial.
    ; Mellbin LG; Rydén L; Riddle MC; Probstfield J; Rosenstock J; Díaz R; Yusuf S; Gerstein HC
    Eur Heart J; 2013 Oct; 34(40):3137-44. PubMed ID: 23999452
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Gerstein HC; Riddle MC; Kendall DM; Cohen RM; Goland R; Feinglos MN; Kirk JK; Hamilton BP; Ismail-Beigi F; Feeney P;
    Am J Cardiol; 2007 Jun; 99(12A):34i-43i. PubMed ID: 17599423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Calles-Escandón J; Lovato LC; Simons-Morton DG; Kendall DM; Pop-Busui R; Cohen RM; Bonds DE; Fonseca VA; Ismail-Beigi F; Banerji MA; Failor A; Hamilton B
    Diabetes Care; 2010 Apr; 33(4):721-7. PubMed ID: 20103550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Macisaac RJ; Jerums G
    Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Monami M; Candido R; Pintaudi B; Targher G; Mannucci E;
    Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
    Margolis KL; O'Connor PJ; Morgan TM; Buse JB; Cohen RM; Cushman WC; Cutler JA; Evans GW; Gerstein HC; Grimm RH; Lipkin EW; Narayan KM; Riddle MC; Sood A; Goff DC
    Diabetes Care; 2014 Jun; 37(6):1721-8. PubMed ID: 24595629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.